Sigyn Therapeutics (SIGY)

Executive Summary

Sigyn Therapeutics is a clinical-stage medical device company developing the Sigyn CardioDialysis™ system, a novel blood purification technology designed to reduce inflammatory molecules and cholesterol-transporting lipoproteins from circulation. The company targets the high unmet need in reducing Major Adverse Cardiovascular Events (MACE) by leveraging existing dialysis clinic infrastructure. Founded in 2019 and based in San Diego, Sigyn is publicly traded under ticker SIGY with a modest market capitalization. The company is exploring strategic initiatives, including potential mergers and asset sales, to maximize shareholder value. Given its early stage and limited financial resources, Sigyn faces significant execution risk, but its proprietary technology addresses a large and growing cardiovascular disease market. Key milestones include preclinical and clinical data readouts, regulatory interactions, and progress on strategic alternatives.

Upcoming Catalysts (preview)

• Q4 2026Clinical Data from CardioDialysis Feasibility Study35% success
• Q2 2026Announcement of Strategic Merger or Asset Sale40% success
• Q3 2026FDA Meeting or Regulatory Pathway Update25% success